Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 84Neoplasm Metastasis 59Prostatic Neoplasms 57Leukemia, Myeloid, Acute 57Melanoma 49Multiple Myeloma 47Colorectal Neoplasms 44Lung Neoplasms 43Pancreatic Neoplasms 39Carcinoma, Non-Small-Cell Lung 38Lymphoma 37Neoplasms 30Myelodysplastic Syndromes 30Leukemia, Lymphocytic, Chronic, B-Cell 30Squamous Cell Carcinoma of Head and Neck 28Lymphoma, Large B-Cell, Diffuse 25Triple Negative Breast Neoplasms 24Ovarian Neoplasms 24Burkitt Lymphoma 21Rectal Neoplasms 20Lymphoma, Follicular 19Colonic Neoplasms 19Uterine Cervical Neoplasms 18Stomach Neoplasms 18Sarcoma 18Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Carcinoma, Renal Cell 18Lymphoma, Mantle-Cell 17Glioma 17Head and Neck Neoplasms 16

Interventions

trifluridine tipiracil drug combination 1berzosertib 1Trifluridine 1Taxes 1Ramucirumab 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Irinotecan 1Endoscopy 1Endoscopic Mucosal Resection 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Clinical Stage III Gastric Cancer AJCC v8 × Biopsy × Clear all
NCT03641313 2026-04-13

Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
17 enrolled 14 charts
Gastrointestinal

Clinical Stage III Gastric Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡